Simultaneous immunopositivity for HBME-1 and Galectin 3, and HBME-1 and CK19 in the diagnosis of differentiated thyroid carcinoma have sensitivities of 85,9 %, and 86.4 % respectively, and specificities of 100 % for both combinations. This evidence concerns the gene LGALS3 and differentiated thyroid carcinoma.